Chordate Medical Holding AB (publ) announced that the first seven patients have been included in the company's post-Market Study PM010. The seven patients have been enrolled by the study at neurology clinics in Hull, Glasgow, Frankfurt, Essen, and Jerusalem. The PM010 study is part of the regulatory requirement for the CE marking of migraine treatment but also holds significant importance in providing information to treating physicians about how often the treatment needs to be administered to different types of patients.